Cerus Management

Management criteria checks 2/4

Cerus' CEO is Obi Greenman, appointed in Apr 2011, has a tenure of 11.58 years. total yearly compensation is $5.18M, comprised of 13.4% salary and 86.6% bonuses, including company stock and options. directly owns 0.99% of the company’s shares, worth €6.58M. The average tenure of the management team and the board of directors is 9.8 years and 4.2 years respectively.

Key information

Obi Greenman

Chief executive officer

US$5.2m

Total compensation

CEO salary percentage	13.4%
CEO tenure	11.6yrs
CEO ownership	1.0%
Management average tenure	9.8yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Obi Greenman's remuneration changed compared to Cerus's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$42m
Mar 31 2022	n/a	n/a	-US$49m
Dec 31 2021	US$5m	US$696k	-US$54m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$61m
Mar 31 2021	n/a	n/a	-US$61m
Dec 31 2020	US$5m	US$670k	-US$60m
Sep 30 2020	n/a	n/a	-US$62m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$69m
Dec 31 2019	US$3m	US$645k	-US$71m
Sep 30 2019	n/a	n/a	-US$71m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$62m
Dec 31 2018	US$3m	US$617k	-US$58m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$56m
Dec 31 2017	US$2m	US$597k	-US$61m
Sep 30 2017	n/a	n/a	-US$63m
Jun 30 2017	n/a	n/a	-US$64m
Mar 31 2017	n/a	n/a	-US$65m
Dec 31 2016	US$2m	US$577k	-US$63m
Sep 30 2016	n/a	n/a	-US$64m
Jun 30 2016	n/a	n/a	-US$65m
Mar 31 2016	n/a	n/a	-US$63m
Dec 31 2015	US$2m	US$554k	-US$56m

Compensation vs Market: Obi's total compensation ($USD5.18M) is above average for companies of similar size in the German market ($USD1.19M).

Compensation vs Earnings: Obi's compensation has increased whilst the company is unprofitable.

CEO

Obi Greenman (55 yo)

11.6yrs

Tenure

US$5,182,371

Compensation

Mr. William M. Greenman, also known as Obi, has been the Chief Executive Officer and President of Cerus Corporation since April 2011. Mr. Greenman served as the Chief Business Officer of Cerus Corporation...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Greenman	President	11.6yrs	US$5.18m	0.99% $ 6.6m
Laurence Corash	Co-Founder & Chief Scientific Officer	7.3yrs	US$1.72m	1.2% $ 8.0m
Kevin Green	VP of Finance & CFO	9.8yrs	US$2.03m	0.13% $ 838.6k
Vivek Jayaraman	Chief Operating Officer	2.7yrs	US$2.38m	0.16% $ 1.1m
Richard Benjamin	Chief Medical Officer	7.3yrs	US$1.74m	0.097% $ 649.4k
Lori Roll	VP of Administration & Corporate Secretary	23.8yrs	no data	no data
Matthew Notarianni	Senior Director of Investor Relations	no data	no data	no data
Chrystal Menard	Chief Legal Officer & General Counsel	9.9yrs	US$804.35k	0.063% $ 422.6k
Lainie Corten	Vice President of Global Marketing	no data	no data	no data
Carol Moore	Senior Vice President of Regulatory Affairs	9.8yrs	US$847.11k	0.13% $ 881.0k
Nina Mufti	VP of Development & Red Blood Cell Program Leader	10.8yrs	no data	no data
Jessica Hanover	Vice President of Corporate Affairs	no data	no data	no data

9.8yrs

Average Tenure

55yo

Average Age

Experienced Management: CU2's management team is seasoned and experienced (9.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Greenman	President	11.6yrs	US$5.18m	0.99% $ 6.6m
Franklin Witney	Independent Director	8.7yrs	US$245.62k	0.068% $ 451.5k
Eric Bjerkholt	Director	4.1yrs	US$218.70k	0.043% $ 290.0k
Daniel Swisher	Independent Chairman	11.4yrs	US$281.37k	0.064% $ 428.0k
Jami K. Nachtsheim	Independent Director	3.7yrs	US$230.33k	0.037% $ 249.5k
Gail Schulze	Independent Director	15.1yrs	US$233.35k	0.027% $ 182.7k
Timothy Moore	Independent Director	4.2yrs	US$220.35k	0.037% $ 244.7k
Ann Lucena	Independent Director	1.3yrs	US$332.11k	0% $ 0
Hua Shan	Director	less than a year	no data	0.017% $ 112.4k

4.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: CU2's board of directors are considered experienced (4.2 years average tenure).

Cerus Management

Management criteria checks 2/4

Key information

Recent management updates

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Cerus Corporation Appoints Hua Shan to its Board of Directors

Insufficient new directors

Cerus Corporation, Annual General Meeting, Jun 01, 2022

Insufficient new directors

Recent updates

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Cerus Corporation to Report Q1, 2024 Results on May 02, 2024

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024

Cerus Corporation to Report Fiscal Year 2023 Results on Mar 05, 2024

Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024

Cerus Corporation has filed a Follow-on Equity Offering in the amount of $96.8 million.

Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023

Cerus Corporation to Report Q3, 2023 Results on Nov 02, 2023

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Cerus Corporation Revises Revenue Guidance for the Year 2023

Cerus Corporation Reiterates Revenue Guidance for the Year 2023

Cerus Corporation to Report Q4, 2022 Results on Feb 28, 2023

Cerus Corporation Provides Revenue Guidance for the Full Year 2023

Cerus Corporation Revises Revenue Guidance for Full Year 2022

Cerus Corporation Announces Health Canada Approval for Intercept Blood System for Platelets with Seven-Day Storage

Cerus Corporation to Report Q3, 2022 Results on Nov 03, 2022

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.047 loss per share (vs US$0.09 loss in 2Q 2021)

Cerus Corporation Reiterates Revenue Guidance for the Full Year 2022

Cerus Corporation to Report Q2, 2022 Results on Aug 04, 2022

Cerus Corporation Appoints Hua Shan to its Board of Directors

First quarter 2022 earnings released: US$0.07 loss per share (vs US$0.10 loss in 1Q 2021)

Cerus Corporation Revises Product Revenue Guidance for the Full Year of 2022

Insufficient new directors

Cerus Corporation, Annual General Meeting, Jun 01, 2022

Cerus Corporation to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Cerus Corporation Provides Product Revenue Guidance for the Year 2022

Cerus Corporation to Report Q4, 2021 Results on Feb 22, 2022

Cerus Corporation Provides Product Revenue Guidance for the Year 2022

Third quarter 2021 earnings released: US$0.072 loss per share (vs US$0.085 loss in 3Q 2020)

Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of Intercept-Based Therapeutic Products

Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.09 loss in 2Q 2020)

Cerus Corporation Revises Product Revenue Guidance for the Year 2021

First quarter 2021 earnings released: US$0.10 loss per share (vs US$0.10 loss in 1Q 2020)

Cerus Corporation Provides Earnings Guidance for the Full Year of 2021

Full year 2020 earnings released: US$0.36 loss per share (vs US$0.51 loss in FY 2019)

Revenue beats expectations

Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age